Shares of Scancell Holdings plc (LON:SCLP – Get Free Report) reached a new 52-week high during trading on Monday . The company traded as high as GBX 13.25 and last traded at GBX 13, with a volume of 3623221 shares. The stock had previously closed at GBX 11.81.
Scancell Trading Up 2.2%
The company has a market capitalization of £137.85 million, a price-to-earnings ratio of -10.54 and a beta of 0.35. The company has a current ratio of 3.42, a quick ratio of 13.01 and a debt-to-equity ratio of -566.79. The business’s 50 day moving average price is GBX 10.29 and its two-hundred day moving average price is GBX 10.05.
Scancell Company Profile
Scancell (LSE:SCLP) is a clinical stage company leveraging two proprietary platforms, Immunobody® and Moditope®, to develop targeted off-the-shelf, patient-accessible active immunotherapies for a cancer-free future. The lead product iSCIB1+ is an Immunobody® DNA active immunotherapy that has demonstrated monotherapy activity in adjuvant melanoma. When combined with checkpoint therapies it showed additional clinical benefit over the checkpoints (CPI) alone in the ongoing Phase 2 SCOPE trial in advanced melanoma.
Recommended Stories
- Five stocks we like better than Scancell
- Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!
- How a Family Trust May Be Able To Help Preserve Your Wealth
- Do not delete, read immediately
- A U.S. “birthright” claim worth trillions – activated quietly
- Executive Order 14330: Trump’s Biggest Yet
Receive News & Ratings for Scancell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scancell and related companies with MarketBeat.com's FREE daily email newsletter.
